HomeCompareBPTSY vs VIG

BPTSY vs VIG: Dividend Comparison 2026

BPTSY yields 444.44% · VIG yields 1.61%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BPTSY wins by $25001.21M in total portfolio value
10 years
BPTSY
BPTSY
● Live price
444.44%
Share price
$0.45
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25001.24M
Annual income
$17,330,574,692.45
Full BPTSY calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.61%
Share price
$215.06
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.3K
Annual income
$175.21
Full VIG calculator →

Portfolio growth — BPTSY vs VIG

📍 BPTSY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPTSYVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPTSY + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BPTSY pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPTSY
Annual income on $10K today (after 15% tax)
$37,777.78/yr
After 10yr DRIP, annual income (after tax)
$14,730,988,488.58/yr
VIG
Annual income on $10K today (after 15% tax)
$136.50/yr
After 10yr DRIP, annual income (after tax)
$148.93/yr
At 15% tax rate, BPTSY beats the other by $14,730,988,339.65/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPTSY + VIG for your $10,000?

BPTSY: 50%VIG: 50%
100% VIG50/50100% BPTSY
Portfolio after 10yr
$12500.64M
Annual income
$8,665,287,433.82/yr
Blended yield
69.32%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPTSY buys
0
VIG buys
0
No recent congressional trades found for BPTSY or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPTSYVIG
Forward yield444.44%1.61%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$25001.24M$32.3K
Annual income after 10y$17,330,574,692.45$175.21
Total dividends collected$24314.87M$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: BPTSY vs VIG ($10,000, DRIP)

YearBPTSY PortfolioBPTSY Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$55,144$44,444.44$11,301$160.59+$43.8KBPTSY
2$288,057$229,052.73$12,752$162.91+$275.3KBPTSY
3$1,426,445$1,118,223.95$14,370$165.02+$1.41MBPTSY
4$6,701,426$5,175,129.87$16,176$166.93+$6.69MBPTSY
5$29,892,686$22,722,160.11$18,188$168.67+$29.87MBPTSY
6$126,709,939$94,724,765.12$20,432$170.25+$126.69MBPTSY
7$510,833,781$375,254,145.76$22,933$171.68+$510.81MBPTSY
8$1,960,465,947$1,413,873,800.93$25,720$172.98+$1960.44MBPTSY
9$7,168,849,807$5,071,151,244.70$28,827$174.15+$7168.82MBPTSY
10$25,001,243,986$17,330,574,692.45$32,288$175.21+$25001.21MBPTSY

BPTSY vs VIG: Complete Analysis 2026

BPTSYStock

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Full BPTSY Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this BPTSY vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPTSY vs SCHDBPTSY vs JEPIBPTSY vs OBPTSY vs KOBPTSY vs MAINBPTSY vs DGROBPTSY vs NOBLBPTSY vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.